Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23845804 | 0.85 | MMP13 (0.36) | MMP13AAK1 | |
| SCHEMBL15845208 | 0.84 | MMP13 (0.38) | MMP13AAK1 | |
| SCHEMBL15845207 | 0.84 | MMP13 (0.38) | MMP13AAK1 | |
| SCHEMBL31114494 | 0.83 | MMP13 (0.34) | MMP13AAK1NPSR1 | |
| SCHEMBL2968992 | 0.81 | AAK1 (0.36) | MMP13AAK1NPSR1 | |
| SCHEMBL2968987 | 0.81 | AAK1 (0.36) | MMP13AAK1NPSR1 | |
| SCHEMBL13707766 | 0.81 | MMP13 (0.38) | MMP13AAK1 | |
| SCHEMBL21134739 | 0.81 | MMP13 (0.38) | MMP13AAK1 | |
| SCHEMBL21153269 | 0.81 | MMP13 (0.38) | MMP13AAK1 | |
| SCHEMBL2966824 | 0.78 | MMP13 (0.35) | MMP13AAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025226861-A1 | CYCLIN INHIBITORS | CIRCLE PHARMA, INC. (US) | 2025-10-30 | — | — | WO | disclosed |
| US-20180265547-A1 | Z-SELECTIVE OLEFIN METATHESIS OF PEPTIDES | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2018-09-20 | — | — | US | disclosed |
| US-20160185821-A1 | Z-SELECTIVE OLEFIN METATHESIS OF PEPTIDES | CALIFORNIA INSTITUTE OF TECHNOLOGY | 2016-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160185821-A1 | Z-SELECTIVE OLEFIN METATHESIS OF PEPTIDES | QPCT, PTMS, MAX | MMP13 842/4885SMN1; SMN2 4149/4885AAK1 2003/4885 |
| US-20180265547-A1 | Z-SELECTIVE OLEFIN METATHESIS OF PEPTIDES | QPCT, PTMS, MAX | MMP13 842/4885SMN1; SMN2 4149/4885AAK1 2003/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.